Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, incombination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: Underlying molecular mechanisms

International Journal of Molecular Medicine

Volumn 34, Issue 2, 2014, Pages 513-532

  Abaza, Mohamed Salah I ^a   Bahman, Abdul Majeed ^a   Al Attiyah, Raja'a J ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Antimitogenic effects; Apoptosis; Cell cycle; Chemosensitization; Pro survival and stress related gene expression; Proteasome inhibitors; Valproic acid

Indexed keywords

AMSACRINE; APHIDICOLIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME C; DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; FLUOROURACIL; HISTONE DEACETYLASE; HOMOHARRINGTONINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PACLITAXEL; PI 1; PR 39; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VALPROIC ACID; VINCRISTINE; ANTICONVULSIVE AGENT; HISTONE DEACETYLASE INHIBITOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CHEMOSENSITIVITY; CHEMOSENSITIZATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTICONVULSANTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; REACTIVE OXYGEN SPECIES; VALPROIC ACID;

EID: 84904252449     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1795     Document Type: Article

References (69)

1. Pitts TM, Morrow M, Kaufman SA, et al: Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8: 342-349, 2009.
2. Göttlicher M, Minucci S, Zhu P, et al: Valproic acid derivatives: A novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001. (Pubitemid 34062289)
3. Tan J, Cang S, Ma Y, et al: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5, 2010.
4. Nolan L, Johnson PWM, Ganesan A, et al: Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99: 689-694, 2008.
5. Dai Y, Chen S, Wang L, et al: Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol 153: 222-235, 2011.
6. Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349-360, 2004.
7. Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657, 2008. (Pubitemid 351469448)
8. Bai J, Demirjian A, Sui J, et al: Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cells. Biochem Biophys Res Commun 4: 1245-1253, 2006. (Pubitemid 44291339)
9. Pei XY, Dai Y and Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 11: 3839-3852, 2004. (Pubitemid 38697620)
10. Emanuele S, Lauricella M, Carlisi D, et al: SAHA induces apoptosis in hepatoma cells and synergistically interact with proteasome inhibitor Bortezomib. Apoptosis 12: 1327-1338, 2007. (Pubitemid 46890392)
11. Abaza MS, Al-Safar A, Al-Sawan S, et al: c-myc anti-sense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. Tumour Biol 29: 287-303, 2008.
12. Abaza MSI: Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells. Exp Ther Med 1: 675-693, 2010.
13. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
14. Kwon SH, Ahn SH, Kim YK, et al: Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277: 2073-2080, 2002. (Pubitemid 34968790)
15. Premkumar DR, Jane EP, Agostino NR, et al: Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog 52: 118-133, 2013.
16. Murphy KM, Streips UN and Lock RB: Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation. J Biol Chem 275: 17225-17228, 2000. (Pubitemid 30430751)
17. Knupfer MM, Pulzer F, Schindler I, et al: Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Anticancer Res 21: 347-351, 2001.
18. Barbetti V, Gozzini A, Cheloni G, et al: Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics 8: 210-219, 2013.
19. Sztanjnkrycer MD: Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40: 789-801, 2002.
20. Chateauvieux S, Morceau F, Dicato M and Diederich M: Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010: 479364, 2010.
21. Kostrouchová M, Kostrouch Z and Kostrouchová M: Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53: 37-49, 2007.
22. Bastian L, Hof J, Pfau M, et al: Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. Clin Cancer Res 19: 1445-1457, 2013.
23. Stypula-Cyrus Y, Damania D, Kunte DP, et al: HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One 8: e64600, 2013.
24. Sidana A, Wang M, Shabbeer S, et al: Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotech 2012: 180363, 2012.
25. Denlinger C, Keller M, Mayo M, et al: Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg 127: 1078-1086, 2004. (Pubitemid 38451941)
26. Drexler HC, Risau W and Konerding MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14: 65-77, 2000. (Pubitemid 30051524)
27. Li B and Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci 97: 3850-3855, 2000. (Pubitemid 30226050)
28. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999. (Pubitemid 29269108)
29. Chandra J, Niemer I, Gilbreath J, et al: Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92: 4220-4229, 1998. (Pubitemid 28544338)
30. Miller CP, Ban K, Dujka ME, et al: NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110: 267-277, 2007. (Pubitemid 47026844)
31. Heider U, Metzler I, Kaiser M, et al: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80: 133-142, 2008.
32. Defoort EN, Kim PM and Winn LM: Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 69: 1304-1310, 2006
33. Rahmani M, Reese E, Dai Y, et al: Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65: 2422-2432, 2005 (Pubitemid 40490154)
34. Dolado I, Swat A, Ajenjo N, et al: p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11: 191-205, 2007. (Pubitemid 46209847)
35. Dasmahapatra G, Lembersky D, Son MP, et al: Carfilzomib interact synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 10: 1686-1697, 2011.
36. Ungerstedt JS, Sowa Y, Xu WS, et al: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 673-678, 2005. (Pubitemid 40282724)
37. Chen Y, McMillan-Ward E, Kong J, et al: Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 15: 171-182, 2008. (Pubitemid 350286185)
38. Krämer OH, Knauer SK, Zimmermann D, et al: Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27: 732-740, 2008. (Pubitemid 351186315)
39. Nile D, Huang K, Yin S, et al: Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells. Leuk Lymphoma 53: 2487-2495, 2012.
40. Proskuryakov SY, Konoplyannikov AG and Gabai VL: Necrosis: a specific form of programmed cell death? Exp Cell Res 283: 1-16, 2003. (Pubitemid 36259891)
41. Hirsch T, Marchetti P, Susin SA, et al: The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15: 1573-1581, 1997. (Pubitemid 27464650)
42. Place RF, Noonan EJ and Giardina C: HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 6: 37, 2005.
43. Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035, 2004. (Pubitemid 40054069)
44. Li XN, Shu Q, Su JM, et al: Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastoma by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4: 1912-1922, 2005. (Pubitemid 43056974)
45. Green DR and Reed JC: Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1312, 1998. (Pubitemid 28406816)
46. Schendel SL, Montal M and Reed JC: Bcl-2 family proteins as ion-channels. Cell Death Differ 5: 372-380, 1998. (Pubitemid 28356813)
47. Bharti AC and Aggarwal BB: Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883-888, 2002. (Pubitemid 35238030)
48. Nalepa G and Wade Harper J: Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 29 (Suppl 1): S49-S57, 2003.
49. Place RF, Noonan EJ and Giardina C: HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: Down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 70: 394-406, 2005. (Pubitemid 40905111)
50. Lewis TS, Shapiro PS and Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139, 1998. (Pubitemid 28193546)
51. Nishioka C, Ikezoe T, Yang J, et al: Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia 22: 1449-1452, 2008. (Pubitemid 352006093)
52. Zhang QL, Wang L, Zhang YW, et al: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23: 1507-1514, 2009.
53. Shelton JG, Blalock WL, White ER, et al: Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 3: 503-512, 2004. (Pubitemid 40278246)
54. Kawamata N, Chen J and Koeffler HP: Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 110: 2667-2673, 2007. (Pubitemid 47523191)
55. Yu C, Rahmani M, Dent P and Grant S: The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295: 555-566, 2004. (Pubitemid 38490507)
56. Yu C, Subler M, Rahmani M, et al: Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biol Ther 2: 544-551, 2003.
57. Yagi Y, Fushida S, Harada S, et al: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 29: 149, 2010.
58. Gatti L, Benedetti V, De Cesare M, et al: Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. J Inorg Biochem 113: 94-101, 2012.
59. Hwang JJ, Kim Ys, Kim T, et al: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs 30: 1434-1442, 2012.
60. Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2: 971-984, 2003.
61. Huang Y and Waxman S: Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin Cancer Res 4: 2503-2509, 1998. (Pubitemid 28477918)
62. Kim MS, Blake M, Baek JH, et al: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63: 7291-7300, 2003. (Pubitemid 37413470)
63. Maggio SC, Rosato RR, Kramer LB, et al: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600, 2004. (Pubitemid 38523917)
64. Witzig TE, Timm M, Stenson M, et al: Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 6: 681-692, 2000. (Pubitemid 30111494)
65. Linares A, Dalenc F, Balaguer P, et al: Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies. J Biomed Biotechnol 2011: 856985, 2011.
66. Munster PN, Thurn KT, Thomas S, et al: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104: 1828-1835, 2011.
67. Atmaca A, Al-Batran SE, Maurer A, et al: Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97: 177-182, 2007. (Pubitemid 47057472)
68. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al: Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222, 2008.
69. Newland SE: The role of bioethics in international prescription drug market: economics and global justice. Penn Bioeth J 2: 8-12, 2006.